Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977)
NCT ID: NCT00988520
Last Updated: 2015-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
38 participants
INTERVENTIONAL
2003-05-31
2003-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First Administration to Man Of Org 25435 a New Intravenous Anesthetic
NCT01062867
Propofol Versus Ketamine for Rapid Sequence Intubation in Critically Ill Patients
NCT05092152
Effects of Desflurane and Propofol During Lung Volume Reduction Surgery
NCT04226625
Sevoflurane Versus Propofol on Optic Nerve Sheath Diameter During Anesthesia in Steep Trendelenburg Position
NCT04289090
Comparison of Sevoflurane and Propofol on ANI
NCT06907823
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.6 mg/kg intubation dose under sevoflurane
Rocuronium bromide
Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
Rocuronium bromide
Intubation dose of 0.6 mg/kg injection
Sevoflurane
0.5-2.0% intravenous maintenance anesthesia
0.9 mg/kg intubation dose under sevoflurane
Rocuronium bromide
Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
Rocuronium bromide
Intubation dose of 0.9 mg/kg injection
Sevoflurane
0.5-2.0% intravenous maintenance anesthesia
continuous dose following 0.6 mg/kg intubation dose + propofol
Rocuronium bromide
Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
Rocuronium bromide
Intubation dose of 0.6 mg/kg injection
Propofol
4010 mg/kg/hr intravenous maintenance anesthesia
continuous dose following 0.9 mg/kg intubation dose + propofol
Rocuronium bromide
Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
Rocuronium bromide
Intubation dose of 0.9 mg/kg injection
Propofol
4010 mg/kg/hr intravenous maintenance anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rocuronium bromide
Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
Rocuronium bromide
Intubation dose of 0.6 mg/kg injection
Rocuronium bromide
Intubation dose of 0.9 mg/kg injection
Sevoflurane
0.5-2.0% intravenous maintenance anesthesia
Propofol
4010 mg/kg/hr intravenous maintenance anesthesia
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects of asa class 1, 2 or 3 for general elective surgery.
* Subjects who are not considered to be pregnant.
* Subjects scheduled for elective surgery under sevoflurane or propofol anesthesia, with anticipated duration of surgery of 2-5 hours.
* Subjects with normal laboratory values for serum electrolytes (Na+, K+, Cl-), BUN, creatinine, total bilirubin, ALP, ALAT and ASAT as judged by the investigator or the sub-investigator.
* Subjects who received an explanation of the trial and agreed informed consent in writing to participate in the trial in advance.
Exclusion Criteria
* Subjects with serum creatinine level greater than 1.6 mg/dL.
* Subjects with severe hepatic dysfunction as a complication or in the history.
* Subjects with known significant metabolic or neuromuscular disorders.
* Subjects with showing dyspnea, airway obstruction or bronchial asthma.
* Subjects with a history of hypersensitivity to pancuronium bromide, vecuronium bromide or bromine.
* Subjects with atopic diseases.
* Subjects who have developed any systemic allergic symptoms related to drugs or general anesthesia.
* Subjects receiving antihistamines and antiallergic agents for 1 month or more.
* Subjects receiving any of the following drugs known to affect on the action of neuromuscular blocking agents on surgery day: calcium antagonists; anticonvulsants; aminoglycoside antibiotics; polypeptide antibiotics; or metronidazole.
* Subjects under hypothermic anesthesia.
* Subjects who participated as research subjects in another trial within the last 6 months or is now participating in other trials.
* Other subjects judged to be ineligible as subjects in this trial by the discretion of the investigator or sub-investigator.
20 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
71103
Identifier Type: -
Identifier Source: secondary_id
P05977
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.